Membranous Nephropathy
Mohamed A. El-Shahawy, MD, MPH, MHA, FASN, CPI
Director and Principal Investigator
Clinical Professor of Medicine (Adjunct), Keck School of Medicine of USC
Trial Overview
This protocol aims at evaluating the efficacy of an investigational medication for adult patients with primary Membranous Nephropathy, in addition to evidence-based standard of care aiming at reducing proteinuria and delay the progress of kidney disease.
Key Inclusion Criteria
- 18 years old or above.
- Biopsy-proven membranous glomerulonephritis or a diagnosis of MN in patients with Nephrotic Syndrome and a positive anti PLA2R antibody test.
- Renal Function ≥30 mL/min/1.73 m2.
Proteinuria of ≥ 0.75 gram/day or higher.
Why Join This Clinical Trial?
– Access to highly experienced Board certified Nephrologists
– Participation is voluntary, and you will learn all details about the protocol by Contacting with our clinical team contact us.
– Clinical trials offer additional care options for your condition, with access to new medicines at no cost.
– Help move science forward and improve human health, wellbeing, and quality of life.
– No cost to participate.
Compensation
- $75.00 per each completed visit
- If you complete all required protocol visits, you will receive up to $2,250.
- Free Transportation will be provided.
Connect with Our Clinical Team
